Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Fondaparinux sodium (Arixtra®) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is indicated in Europe for preventing thrombus formation in patients with acute coronary syndromes (ACS; the focus of this review), including those with ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina.
The large (n = 20 078), well designed OASIS-5 trial showed that subcutaneous fondaparinux 2.5 mg/day for ≤8 days was noninferior to subcutaneous enoxaparin 1 mg/kg twice daily (once daily in those with renal dysfunction) in reducing death or ischemic events at 9 days and the efficacy was maintained for up to 6 months (study end) in patients with unstable angina or NSTEMI. During this time, major bleeding occurred in fewer fondaparinux than enoxaparin recipients, resulting in a benefit: risk balance favoring fondaparinux. The incidence of death or reinfarction at 30 days was significantly lower in recipients of subcutaneous fondaparinux 2.5 mg/day than in those who received usual care (including unfractionated heparin [UFH] treatment as indicated) in patients with STEMI in the large (n > 12 000) OASIS-6 trial. There were no differences in the incidence of major bleeding between these groups, resulting in a benefit: risk balance favoring fondaparinux.
The specificity and selectivity of fondaparinux, combined with its long half-life and 100% bioavailability, allows once-daily anticoagulation without the need for monitoring activated clotting time. Subcutaneous fondaparinux was noninferior to enoxaparin treatment in patients with unstable angina or NSTEMI, and was more effective than usual care in those with STEMI. Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term. Thus, overall, clinical evidence suggests that fondaparinux has a valuable place in the treatment of patients with ACS.
Fondaparinux inhibits thrombus formation by binding strongly to antithrombin III, enhancing its inhibitory activity, and thus indirectly inhibiting free factor Xa and interrupting the blood coagulation cascade. Coagulation parameters, such as activated partial thromboplastin time, are not affected. Activated factor VII has been shown to partially reverse the anticoagulant effects of fondaparinux in humans.
Fondaparinux is rapidly and completely absorbed following subcutaneous administration, demonstrating 100% bioavailability. The pharmacokinetic profile is linear over a 2–8 mg dose range. Peak plasma fondaparinux concentrations are obtained ≈2 hours following single or multiple subcutaneous doses. Steady-state fondaparinux concentrations are reached after 3–4 days of repeat once-daily administration. Distribution of fondaparinux may be limited to the vascular compartment; the volume of distribution is 8.2–10.2 L.
Fondaparinux does not appear to be metabolized and, in vitro, does not inhibit cytochrome P450 isoenzymes. Elimination is primarily by renal excretion. Fondaparinux clearance is reduced in patients with renal impairment, and clearance is lower in patients weighing <50 kg.
Subcutaneous fondaparinux 2.5 mg/day for ≤8 days was noninferior to subcutaneous enoxaparin 1 mg/kg twice daily in patients with ACS involving unstable angina or NSTEMI. The primary composite endpoint comprising death, myocardial infarction (MI) or refractory ischemia had occurred in 5.8% and 5.7% of patients in the respective groups at day 9 in the OASIS-5 trial and the incidence remained similar between treatment groups to trial end at 180 days.
In patients with ACS presenting as STEMI who received subcutaneous fondaparinux 2.5 mg/day for ≤8 days (given intravenously on day 1), the incidence of death or reinfarction was significantly less than in those who received usual care (placebo or UFH therapy) in the OASIS-6 trial. The primary composite endpoint comprising death or reinfarction at 30 days occurred in 9.7% and 11.2% of patients in the respective groups (p < 0.001) and the between-group difference remained statistically significant from day 9 to study end (3–6 months).
When subcutaneous fondaparinux 2.5 mg/day was given during percutaneous coronary intervention (PCI) to subgroups in these two trials, therapeutic outcomes were similar to those seen with enoxaparin (in patients with unstable angina or NSTEMI) or UFH (in patients with STEMI).
The tolerability profile of subcutaneous fondaparinux in patients with ACS is similar to that in patients undergoing orthopedic or abdominal surgery, or in medical patients at risk of thromboembolic complications.
The main adverse effect of fondaparinux is bleeding. In the OASIS-5 trial, major bleeding occurred in significantly fewer patients with unstable angina or NSTEMI receiving subcutaneous fondaparinux 2.5 mg/day than those receiving subcutaneous enoxaparin 1 mg/kg twice daily for ≤8 days (2.2% vs 4.1% at 9 days; p < 0.001). The difference became apparent at day 5 and remained significant for up to 180 days. In patients with STEMI in the OASIS-6 trial, there were no differences in the incidence of major bleeding between the fondaparinux and usual care groups (1.8% vs 2.1%).
Benefit: risk calculations using multiple endpoints comprising death/MI/refractory ischemia/major bleeding (OASIS-5) or death/MI/severe bleeding (OASIS-6) indicated that these endpoints occurred in significantly fewer fondaparinux recipients than enoxaparin recipients with unstable angina or NSTEMI (7.3% vs 9.0% at 9 days; p < 0.001), and in usual care recipients with STEMI (7.7% vs 9.2% at 9 days; p < 0.01).
In patients undergoing PCI in the OASIS-5 trial, the incidence of catheter-related thrombosis was higher in fondaparinux recipients than in those who received enoxaparin alone (0.9% vs 0.4%; p < 0.001); however, when UFH was administered at the time of PCI, this complication was virtually eliminated.
- Alexander JH, Singh KP. Inhibition of Factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs 2005; 5(5): 279–90. CrossRef
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the managment of patients with acute myocardial infarction). Developed in collaboration with the Canadian Cardiovascular Society. Circulation 2004 Aug 3; 110: 588–636.
- Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7(2): 95–116. CrossRef
- Farooq M, Qureshi AS, Squire IB. Early management of ST elevation myocardial infarction: a review of practice. Expert Opinion on Pharmacotherapy 2007; 8(4): 401–13. CrossRef
- Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes: variations in practice and outcome. Findings from the global registry of acute coronary events (GRACE). Eur Heart J 2002; 23(15): 1177–89. CrossRef
- Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: the taskforce on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66. CrossRef
- Bassand J-P, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598–660. CrossRef
- Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation 2007 Aug 6.
- Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag 2007; 3(3): 321–9.
- Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64(14): 1575–96. CrossRef
- Robinson DM, Wellington K. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Am J Cardiovasc Drugs 2005; 5(5): 335–46. CrossRef
- Bauer KA. New pentassaccharides for prophylaxis of deep vein thrombosis. Chest 2003; 124(6): 364S–70S. CrossRef
- Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15(1): 1–26. CrossRef
- Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86(1): 1–36. CrossRef
- European Medicines Agency. Fondaparinux sodium: Arixtra™ 1.5mg/0.3mL solution for injection; summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/arixtra/H-403-PI-en.pdf [Accessed 2008 Mar 28].
- Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentassarcharide. J Med Chem 1997; 40: 1600–7. CrossRef
- Lormeau JC, Herault JP, Gaich C, et al. Determination of the antifactor Xa activity of the synthetic pentasaccharide SR 9017A/ORG 31540 and of two structural analogues. Thromb Res 1997; 85(1): 67–75. CrossRef
- Olson ST, Bjork I, Sheffert R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin proteinase reactions. J Biol Chem 1992 Jun; 267(18): 12528–38.
- Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91(11): 4197–205.
- Bendetowicz AV, Bara L, Samama MM, et al. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res 1990; 58(5): 445–54. CrossRef
- Boneu B, Necciari J, Cariou R, et al. Pharmacokinteics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74(6): 1468–73.
- Gerotziafas GT, Bara L, Bloch MF, et al. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor Vila and prothrombin activation after coagulation of human plasma. Blood Coagul Fibrinolysis 1998; 9(7): 571–80. CrossRef
- Gerotziafas GT, Elalamy I, Depasse F, et al. On the mechanism of inhibition of tissue factor pathway by the synthetic pentassacharise during coagulation of human plasma. Blood Coagul Fibrinolysis 2003; 14(7): 633–8. CrossRef
- Pieters J, Lindhout T, Willems G, et al. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralisation in plasma. Blood 1990; 76(3): 549–54.
- Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemostat 1996 Jul; 76(1): 5–8.
- Olson ST, Swanson R, Raub-Segall E, et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems: comparison with heparin and low-molecular weight heparin. Thromb Haemost 2004; 92: 929–39.
- European Medicines Agency. Scientific discussion (of Arixtra) [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Mar 28].
- Walenga JM, Fareed J. Relative contribution of factor Xa and factor IIa: inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides. Thromb Haemorrh Disorders 1991; 3(2): 53–9.
- Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood 1994; 84(8): 2571–7.
- Messmore HL, Griffin B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989; (556): 217–31. CrossRef
- Bijsterveld MD, Moons AH, Boekholdt M, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002 Nov 12; 106: 2550–4.
- US Food and Drug Administration. Fondaparinux Sodium: Atrixtra® injection prescribing information [online]. Available from URL: http://www.fda.gov/ cder/foi/label/2005/021354s010LbL.pdf [Accessed 2008 Mar 28].
- Faaij RA, Burgraaf J, Schoemaker RC, et al. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol 2002; 54: 304–8. CrossRef
- Ollier C, Faaij RA, Santoni A, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 31–7. CrossRef
- Mant T, Fournie P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 39–45. CrossRef
- Donat F, Duret JP, Santoni A. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1–9. CrossRef
- Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation 2005 Mar 22; 111(11): 1390–7.
- Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006 Apr 5; 295(13): 1519–30. CrossRef
- Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 Apr 6; 354(14): 1464–76.
- Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) study. J Am Coll Cardiol 2004 Jun 16; 43(12): 2183–90.
- Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007 Oct 30; 50(18): 1742–51.
- Fox KA, Mehta SR. Impact of renal function on the benefit-risk ratio of fondaparinux in patients with non-ST elevation acute coronary syndromes in the OASIS-5 trial [abstract no. P-T-682]. 21st Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6; Geneva.
- Sculpher MJ, Lozano-Ortega G, Sambrook JC, et al. Cost-effectiveness in France of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome: an analysis using data from OASIS-5 [abstract no. P4804]. Annual Congress of the European Society of Cardiology; 2007 Sep 1; Vienna.
- Peters R, Mehta SR. Mortality benefit of fondaparinux versus enoxaparin in diabetic patients with non-ST elevation acute coronary syndromes: a subanalysis of OASIS-5 [abstract no. P-M-683]. 21st Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6; Geneva.
- Peters RJ, van Rees Vellinga T, Bassand JP, et al. Efficacy and safety of fondaparinux in elderly patients with ST segment elevation myocardial infarction: data from the OASIS 6 trial [abstract no. 1025–138]. J Am Coll Cardiol 2007 Mar 6; 49 Suppl. 9A: 242.
- Fox KAA, Bassand J-P, Mehta S, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2007; 147(5): 304–10.
- Granger CB, Wallentin L, Avezum A, et al. Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes [abstract no. 2376]. Eur Heart J 2006 Sep; 27 Suppl.: 448.
- Hamon M, Mehta SK, Steg G, et al. Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: insights from OASIS-5 trial [abstract no. 2654]. Circulation 2006 Oct 31; 114 Suppl. 18: 552.
- Peters RJ, Joyner C, Bassand JP, et al. Fondaparinux versus control (placebo or unfractionated heparin) as an adjunct to thrombolytic therapy in acute myocardial infarction: an OASIS 6 Substudy [abstract no. 3071; plus poster]. Circulation 2006; 114 Suppl. 18: 699.
- Jolly S, Mehta SR, Wallentin L, et al. The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial [abstract no. P1265]. Annual Congress of the European Society of Cardiology; 2007 Sep 1; Vienna. Eur Heart J 2007; 28: 187.
- Genth-Zotz S, Rupprecht H-J, Mehta SR, et al. Early benefit of fondaparinux in patients with non-ST elevation acute coronary syndromes: a secondary analysis of the OASIS-5 trial [abstract no. V1744]. 73rd Annual Meeting of the German Society for Cardiology, Heart and Circulation Research; 2007 Apr 12–14; Mannheim.
- Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2008 Jan; 51(2): 210–47.
- Bates ER. New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. Curr Cardiol Rep 2007 Jul; 9(4): 289–97. CrossRef
- Antman EM. Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention? Nat Clin Pract Cardiovasc Med Epub 2008 Feb 19.
- Peacock WF, Hollander JE, Smalling RW, et al. Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. Am J Emerg Med 2007; 25(3): 353–66. CrossRef
- Fondaparinux Sodium
American Journal of Cardiovascular Drugs
Volume 8, Issue 2 , pp 113-125
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
- 2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA